BioBiz Buzz
BioBiz Buzz offers exclusive insights into the biotech, pharma, and medtech industries through interviews with top executives and visionaries.
Providing thought-provoking podcasts covering topics such as scientific advancements, emerging technologies, and market trends, to keep listeners informed about the latest developments in life sciences.
Disclaimer
https://biobizbuzz.com/disclaimer/
- Update frequency
- every 11 days
- Average duration
- 23 minutes
- Episodes
- 9
- Years Active
- 2025
9. Beyond Billion-Dollar Bets: How Affibody Might Solve Radioligand Therapy's Greatest Challenges
The radioligand therapy market will be worth $42 billion by 2032. However, beneath the headline-grabbing acquisitions lies a complex web of technical and commercial challenges that threaten to limit …
8. Revolutionizing Cancer Drug Development with AI: How BioCopy is Using Physics to Rewrite the Rules of Biotech
By 2040, the World Health Organization predicts that one in two people will be diagnosed with cancer in their lifetime. Yet the traditional pharmaceutical industry remains trapped in a devastating cy…
7. Exploring new possibilities in reproductive medicine
ReproNovo demonstrated continued investor interest in the area of reproductive medicine by closing a $65 million Series A round earlier this year. In this episode, ReproNovo’s CEO and co-founder Jean…
6. Device Intelligence: How AI and Data Are Powering MedTech’s Next Frontier
In this episode of BioBiz Buzz, your host Shani Alexander is joined by Werner Lanthaler, founder and CEO of WLan Holding, to chart the seismic transformation underway in medical technology. Discover …
5. Breaking New Ground in Pain Management with Non-Addictive Opioid Alternatives
As the opioid crisis continues to devastate communities worldwide, millions suffering from chronic and neuropathic pain face a critical dilemma: enduring debilitating pain or risking addiction with t…
4. The Power of International Alliances: Unpacking the Swiss Biotech Report 2025
In 2024, despite a challenging global financial climate, Switzerland’s biotech sector showed remarkable resilience, maintaining steady revenues of CHF 7.2 billion while achieving a 22% increase in ca…
3. Rewriting the Future of Rare Cardiovascular Disease Through Epigenetic Innovation
In this episode of BioBiz Buzz, your host Mike Ward sits down with Sten R. Sörensen, CEO of Cereno Scientific, to explore how the Swedish biotech is pioneering a new era in rare cardiovascular and pu…
2. Breaking Barriers in Sexual Health: Dicot Pharma’s LIB-01 and the Future of ED Treatment
This episode of BioBiz Buzz spotlights the rapidly growing global markets for erectile dysfunction (ED) and premature ejaculation (PE), conditions impacting over 500 million men worldwide.
Your host …
1. CRISPR Unleashed: How Caszyme Is Redefining the Future of Gene Editing
This episode of BioBiz Buzz features Dr. Monika Paule, CEO and co-founder of Caszyme, a pioneering Lithuanian biotech company at the forefront of CRISPR-Cas technology.
Your host Mike Ward explores h…